- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.04. | Lexaria Bioscience, Biosig Technologies, BIMI Holdings among healthcare movers | 1 | Seeking Alpha | ||
| 16.04. | Lexaria gets ethics board okay for oral GLP-1 study | 1 | Seeking Alpha | ||
| 16.04. | Lexaria Bioscience Corp.: Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study | 448 | ACCESSWIRE | Human Pilot Study #2 (GLP-1-H24-2) Approved KELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug... ► Artikel lesen | |
| 10.04. | Lexaria Bioscience Corp expected to post a loss of 13 cents a share - Earnings Preview | 1 | Reuters | ||
| 09.04. | Lexaria Bioscience Corp. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 02.04. | Lexaria Bioscience Corp.: Lexaria Awarded New Patents | 120 | ACCESSWIRE | Lexaria receives new patents in the fields of epilepsy and anti-viral agentsKELOWNA, BC / ACCESSWIRE / April 2, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria")... ► Artikel lesen | |
| 21.03. | Lexaria to Present at The LD Micro Invitational XIV | 210 | Newsfile | Kelowna, British Columbia--(Newsfile Corp. - March 21, 2024) - Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces... ► Artikel lesen | |
| 15.03. | Lexaria Bioscience Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.03. | Lexaria appoints Nelson Cabatuan as CFO | 1 | Seeking Alpha | ||
| 14.03. | Lexaria Bioscience Corp.: Lexaria Appoints Nelson Cabatuan as Chief Financial Officer | 324 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / March 14, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment... ► Artikel lesen | |
| 12.03. | Lexaria Bioscience files to sell 1.61M shares of common stock for holders | 1 | Seeking Alpha | ||
| 12.03. | Lexaria Bioscience Corp. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 12.03. | FGEN, LEXX and SGLY among mid-day movers | 1 | Seeking Alpha | ||
| 07.03. | Lexaria Bioscience Corp.: Lexaria Awards Contract For Next GLP-1 Human Pilot Study | 549 | ACCESSWIRE | First-ever dissolvable DehydraTECH-GLP-1 oral dose formulation to be testedRybelsus® semaglutide will act as the positive controlKELOWNA, BC / ACCESSWIRE / March 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)... ► Artikel lesen | |
| 05.03. | Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes | 1 | Seeking Alpha | ||
| 05.03. | Lexaria Bioscience Corp.: Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 | 797 | ACCESSWIRE | Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be testedChronic dosing over a 12-week treatment periodWill assess weight loss and blood glucose level controlEfficacy through possible... ► Artikel lesen | |
| 04.03. | Lexaria Bioscience Corp.: 7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study | 1.300 | ACCESSWIRE | KELOWNA, BC / ACCESSWIRE / March 4, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, informs that its wholly-owned... ► Artikel lesen | |
| 01.03. | Lexaria Bioscience Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.03. | Lexaria slips despite FDA nod to test blood pressure drug | 1 | Seeking Alpha | ||
| 01.03. | FDA clears Lexaria's hypertension trial for DehydraTECH-CBD | 2 | Investing.com |
Seite:
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORPEA | 12,572 | -0,77 % | EMEIS PURSUES ITS REFOUNDATION: 2023 Consolidated Financial Results of ORPEA S.A. | Significant improvement in non-financial indicators, with major advances for employees, residents and patients
Health and safety: decline in the work-related accident frequency rate, at 24.8... ► Artikel lesen | |
| NANO-X IMAGING | 9,290 | 0,00 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| GLOBAL HEMP GROUP | 0,029 | 0,00 % | XFRA GHG0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGLOBAL HEMP GROUP... ► Artikel lesen | |
| BUTTERFLY NETWORK | 0,740 | 0,00 % | ThinkSono Ltd: ThinkSono Releases Real-Time DVT AI Training Solution for Butterfly Network's Handheld Ultrasound Devices | LONDON, ENGLAND / ACCESSWIRE / April 23, 2024 / ThinkSono, a pioneering provider of AI-driven medical imaging solutions, is proud to announce the release of ThinkSono AI Training, a deep vein thrombosis... ► Artikel lesen | |
| GOODRX | 6,970 | +4,65 % | GoodRx Reports Fourth Quarter and Full Year 2023 Results | SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial... ► Artikel lesen | |
| JOINT CORP | 12,610 | +2,02 % | The Joint Corp. to Host Conference Call on Thursday, May 2nd to Discuss First Quarter 2024 Results | ||
| CARMAT | 3,800 | +0,26 % | CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the Second Quarter of 2024 | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| PROGYNY | 32,370 | 0,00 % | Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care | ||
| HYPERFINE | 0,810 | 0,00 % | Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| MIMEDX | 6,500 | +2,20 % | MiMedx Group, Inc: MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results | Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million One-Time Non-Cash Tax Benefit Fourth Quarter... ► Artikel lesen | |
| BIOMERICA | 0,720 | -0,65 % | Biomerica, Inc.: Biomerica Reports Third Quarter 2024 Financial Results | Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented... ► Artikel lesen | |
| ATRION | 374,00 | -0,53 % | Dividendenbekanntmachungen (14.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
| ATRICURE | 23,150 | +1,94 % | AtriCure upgraded at Oppenheimer on valuation | ||
| AMWELL | 0,542 | 0,00 % | Amwell® to Report First Quarter 2024 Operating Results May 1 | ||
| TALKSPACE | 3,140 | 0,00 % | Talkspace to Report First Quarter 2024 and Host Conference Call |
Das Unternehmen LEXARIA BIOSCIENCE CORP kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
